Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining thalidomide with interferon alfa in
treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Thalidomide may
stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere
with the growth of cancer cells. Combining thalidomide with interferon alfa may kill more
tumor cells